# Moderna Shares Jump 11.04% Before Melanoma Trial Data

> Moderna shares rise 11.04% as melanoma trial data approaches.
- Title: Moderna Shares Jump 11.04% Before Melanoma Trial Data
- Summary: Moderna shares rise 11.04% as melanoma trial data approaches. Moderna stock climbed 11.04% ahead of Phase 3 melanoma trial results presentation.
- Keywords: moderna, merck, melanoma, phase 3, intismeran autogene, keytruda, trials, stock, shares, investing, tokenpost, crypto
- Source: TokenPost — https://tokenpost.com/news/investing/36860
- Published: 2026-10-21T17:06:53+00:00
- Read time: 1 min
- Topics: moderna, merck, melanoma, phase 3, intismeran autogene, keytruda, trials, stock, shares, investing, tokenpost, crypto
## Moderna Shares Rise
Moderna shares climbed 11.04% over two sessions, closing at $242.08 on Oct. 20 as investors awaited detailed Phase 3 results for its melanoma treatment with Merck.
## Trial Results Scheduled
Detailed trial results for intismeran autogene with Keytruda are set for presentation Saturday, Oct. 24, at 10:30 a.m. ET.
## Stock Performance
Shares rose 4.07% on Oct. 19 and 6.69% on Oct. 20, climbing 284.5% from $62.96 on Aug. 18.
## Key takeaway

Moderna stock climbed 11.04% ahead of Phase 3 melanoma trial results presentation.